NEW YORK, June 6 (GenomeWeb News) - Cell Signalling Technology has partnered with Bio-Rad Laboratories to develop phosphoprotein assays to be commercialized with Bio-Rad's bead-based assays, CST said today.
Under the partnership, CST will develop antibodies for kinase activation and protein phosphorylation assays to be used in Bio-Rad's multiplex bead-based assays for the Bio-Plex suspension array system.
CST will develop a broader array of antibodies for the Bio-Plex platform. Bio-Rad's phosphoprotein assays are optimized to simultaneously assess kinase and signaling protein activation states and provide critical tools for disease research and drug development.
Financial details were not disclosed.